|
CHAPTER 1 EXECUTIVE SUMMARY
- Datamonitor insight into the non-Hodgkins lymphoma market
- Epidemiology and etiology
- Classification and prognosis
- Follicular lymphoma
- Diffuse large B-cell lymphoma
- Mantle cell lymphoma
- Peripheral T-cell lymphoma
- Pipeline products
CHAPTER 2 INTRODUCTION
- Disease overview
- Epidemiology
- NHL etiology
- Disease classification
- Staging
- Prognosis
- Gene expression profiling
CHAPTER 3 CURRENT TREATMENT CONTROVERSIES
- Follicular lymphoma
- Induction treatment
- Limited-stage disease
- Advanced-stage disease
- Maintenance rituximab?
- Rituximab Pharmacokinetics
- Disease relapse
- Radioimmunotherapy (RIT)
- Blood or marrow stem cell transplantation
- Myeloablative chemotherapy using RIT
- Non-myeloablative allogeneic SCT
- Diffuse large B-cell lymphomas (DLBCL)
- Induction therapy
- Disease relapse
- Front-line dose-intensive treatment?
- Dose-intensive CHOP?
- Radioimmunoconjugates (RIC)
- Gemzar
- Mantle cell lymphoma (MCL)
- Induction treatment
- Radioimmunotherapy (RIT)
- Maintenance treatment
- Peripheral T-cell NHL
- Induction treatment
- Bioimmunotherapy
- Alemtuzumab (Campath)
- Ontak
CHAPTER 4 PIPELINE DRUGS
- Epratuzumab
- Profile
- Drug overview
- Clinical trial data
- Datamonitor comments
- Bortezomib
- Profile
- Drug overview
- Clinical data
- Datamonitor comments
- Pixantrone (BBR-2778)
- Profile
- Drug overview
- Clinical data
- Datamonitor comments
- Genasense (oblimersen sodium)
- Profile
- Drug overview
- Clinical trial data
- Datamonior comments
- FK-228 (depsipeptide, FR-901228)
- Profile
- Drug overview
- Clinical trial data
- Datamonitor comments
- Vaccine therapy
- MyVax Personalized Immunotherapy (GTOP-99)
- Clinical data
- Oncophage (HSPCC-96)
- Clinical data
- Datamonitor comments
CHAPTER 5 APPENDIX
- Opinion leader interview transcripts
- Contributing experts
- Opinion leader 1
- Opinion leader 2
- Opinion leader 3
- Opinion leader 4
- Opinion leader 5
- Opinion leader 6
- Bibliography
- OncoVision
- About Datamonitor
- About Datamonitor Healthcare
- Datamonitor Healthcares research and analysis methodologies
- Datamonitor Healthcares therapy area capabilities
- About the Oncology analysis team
- Key therapy team members
- Nish Saini, Senior Oncology Analyst
- Disclaimer
- List of Tables
- Table 1: Gene rearrangements in subtypes of NHL
- Table 2: Distribution of histological subtypes of NHL
- Table 3: Five-year overall survival based on IPI
- Table 4: Comparison of radioisotopes in Bexxar and Zevalin
- Table 5: Summary of Phase II and III Zevalin studies
- Table 6: Summary of selected Phase II and III Bexxar studies
- Table 7: Incidence of non-hematological toxicity for the RICs
- Table 8: Ongoing studies evaluating RIC
- Table 9: Summary of GELA and MiNT trial results
- Table 10: Gemcitabine in lymphoma
- Table 11: Phase I/II study of epratuzumab: Leonard et al., 2002
- Table 12: Phase II study of Velcade in NHL: Owen et al., 2003
- Table 13: Phase II study of Velcade in NHL: Goy et al., 2003
- Table 14: Phase II trial of Genasense +/- CHOP-R in MCL: Leonard et
al., 2003
- List of Figures
- Figure 1: NHL incidence/mortality in the seven major markets to 2012
- Figure 2: Incidence of NHL by country, 2004-12
- Figure 3: NHL incidence and mortality in the seven major markets by
age group, 2004
- Figure 4: NHL incidence/mortality in the seven major markets to 2012
- Figure 5: Incidence of NHL by country, 2004-12
- Figure 6: NHL incidence and mortality by age group, 2004
- Figure 7: NHL classification: working formulation
- Figure 8: REAL classification of NHL
- Figure 9: WHO classification of NHL
- Figure 10: Proposed WHO classification of NHL
- Figure 11: Ann Arbor staging of NHL
- Figure 12: Treatment of stages II, III, IV DLBCL
- Figure 13: Treatment of stage I DLBC
- Figure 14: Phase II trial of Genasense +/_ CHOP-R in MCL: Leonard et
al., 2003
- Figure 15: Manufacture of MyVax
|
Related Report
|
View Cart
